Lenalidomide enhances anti-myeloma cellular immunity
Cancer Immunology, Immunotherapy, 07/03/2012
Clinical Article
Luptakova K et al. – The findings indicate that lenalidomide enhances the immunologic milieu in patients with myeloma by promoting T–cell proliferation and suppressing inhibitory factors, and thereby augmenting responses to a myeloma–specific tumor vaccine.



